Go Pro
NASDAQ:OSRH

OSR Q3 2025 Earnings Report

OSR logo
$0.25 -0.03 (-9.75%)
Closing price 04:00 PM Eastern
Extended Trading
$0.22 -0.03 (-11.60%)
As of 06:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OSR EPS Results

Actual EPS
-$0.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

OSR Revenue Results

Actual Revenue
$0.63 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

OSR Announcement Details

Quarter
Q3 2025
Time
During Market Hours
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

OSR Earnings Headlines

They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
OSR Holdings Stock Price History
See More OSR Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OSR? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OSR and other key companies, straight to your email.

About OSR

OSR (NASDAQ:OSRH) Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.

View OSR Profile